For many professionals, a successful career within the very competitive world of healthcare PR would be enough. But for AnnaMaria DeSalva, it is only part of her accomplishments. Last year, she was chosen to be the only PR professional on the FDA's Risk Communication Advisory Committee, which is designed to look at how the agency can better communicate risk to the general public about the many products it regulates. Certainly the FDA has been under enormous scrutiny in recent years, so DeSalva's role on the committee has the potential to alter the way the government agency communicates with the public. Her experience there is also bound to benefit her clients, which include Pfizer, Amgen, Merck, Medtronic, and the National Breast Cancer Coalition. In addition to her work with the FDA, she is also chair of the PRSA's Thought Leadership Committee; is a founding member of the World Summit against Cancer's scientific committee; and serves as director of the nonprofit Project Sunshine.